Stryker (SYK) Set to Release Earnings on Thursday

Stryker (NYSE:SYK) is expected to announce its Q3 2026 results after the market closes on Thursday, October 29th. Analysts expect Stryker to announce earnings of $3.55 per share and revenue of $6.62 billion for the quarter. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, October 29, 2026 at 4:30 PM ET.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. The firm had revenue of $6.59 billion for the quarter, compared to analysts’ expectations of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%. The business’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.13 EPS. On average, analysts expect Stryker to post $14.93 EPS for the current fiscal year and $16.60 EPS for the next fiscal year.

Stryker Stock Performance

Stryker stock opened at $306.50 on Tuesday. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. The company has a market capitalization of $117.56 billion, a P/E ratio of 31.76, a PEG ratio of 1.98 and a beta of 0.78. The stock’s 50 day moving average is $295.95 and its 200 day moving average is $326.09. Stryker has a twelve month low of $267.00 and a twelve month high of $389.33.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker’s payout ratio is presently 36.48%.

Insider Buying and Selling

In related news, Director Ronda Stryker sold 300,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $335.90, for a total value of $100,770,000.00. Following the transaction, the director directly owned 2,301,375 shares of the company’s stock, valued at approximately $773,031,862.50. This represents a 11.53% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Dylan Crotty sold 441 shares of the stock in a transaction on Friday, August 21st. The shares were sold at an average price of $328.61, for a total value of $144,917.01. Following the sale, the insider owned 6,102 shares in the company, valued at approximately $2,005,178.22. This represents a 6.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 351,267 shares of company stock worth $118,197,701 in the last three months. Insiders own 4.60% of the company’s stock.

Analysts Set New Price Targets

SYK has been the topic of several analyst reports. Citizens Jmp dropped their target price on Stryker from $440.00 to $400.00 and set a “market outperform” rating on the stock in a report on Monday, August 3rd. BTIG Research reduced their price target on Stryker from $358.00 to $316.00 and set a “buy” rating for the company in a report on Monday, October 12th. Wolfe Research lowered Stryker from an “outperform” rating to a “peer perform” rating in a research report on Thursday, August 13th. Sanford C. Bernstein reiterated a “market perform” rating on shares of Stryker in a research note on Wednesday, October 7th. Finally, BMO Capital Markets reissued an “outperform” rating and set a $317.00 price objective on shares of Stryker in a research report on Wednesday, September 9th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, Stryker presently has an average rating of “Moderate Buy” and a consensus target price of $369.00.

About Stryker

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.